Rudolph Navari to Neurokinin-1 Receptor Antagonists
This is a "connection" page, showing publications Rudolph Navari has written about Neurokinin-1 Receptor Antagonists.
Connection Strength
5.461
-
Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review. Expert Opin Drug Saf. 2020 Feb; 19(2):205-210.
Score: 0.680
-
The safety of rolapitant for the treatment of nausea and vomiting associated with chemotherapy. Expert Opin Drug Saf. 2019 Dec; 18(12):1127-1132.
Score: 0.677
-
HTX-019: polysorbate 80- and synthetic surfactant-free neurokinin 1 receptor antagonist for chemotherapy-induced nausea and vomiting prophylaxis. Future Oncol. 2019 Jan; 15(3):241-255.
Score: 0.631
-
Rolapitant hydrochloride: prophylactic treatment for chemotherapy-induced nausea and vomiting. Drugs Today (Barc). 2016 Aug; 52(8):431-438.
Score: 0.542
-
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy. Biochim Biophys Acta. 2015 Oct; 1848(10 Pt B):2738-46.
Score: 0.494
-
Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2008 Nov; 8(11):1733-42.
Score: 0.317
-
Casopitant, a neurokinin-1 receptor antagonist with anti-emetic and anti-nausea activities. Curr Opin Investig Drugs. 2008 Jul; 9(7):774-85.
Score: 0.309
-
Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Expert Opin Investig Drugs. 2007 Dec; 16(12):1977-85.
Score: 0.297
-
Role of neurokinin-1 receptor antagonists in chemotherapy-induced emesis: summary of clinical trials. Cancer Invest. 2004; 22(4):569-76.
Score: 0.226
-
Use of placebos in delayed-emesis studies. J Clin Oncol. 1999 May; 17(5):1648-50.
Score: 0.164
-
Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med. 1999 Jan 21; 340(3):190-5.
Score: 0.161
-
Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations. Drug Des Devel Ther. 2017; 11:2621-2629.
Score: 0.146
-
Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients. Paediatr Drugs. 2017 Jun; 19(3):213-222.
Score: 0.143
-
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016 Apr 07; 374(14):1356-67.
Score: 0.132
-
Rolapitant for the treatment of chemotherapy-induced nausea and vomiting. Expert Rev Anticancer Ther. 2015; 15(10):1127-33.
Score: 0.127
-
Management of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents. Drugs. 2013 Mar; 73(3):249-62.
Score: 0.107
-
Prevention of emesis from multiple-day and high-dose chemotherapy regimens. J Natl Compr Canc Netw. 2007 Jan; 5(1):51-9.
Score: 0.070
-
Emerging drugs for chemotherapy-induced emesis. Expert Opin Emerg Drugs. 2006 Mar; 11(1):137-51.
Score: 0.066
-
Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents. J Support Oncol. 2003 Jul-Aug; 1(2):89-103.
Score: 0.055
-
Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer. 2002 Jun 01; 94(11):3032-41.
Score: 0.051
-
Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. Support Care Cancer. 2017 01; 25(1):85-92.
Score: 0.034
-
Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. Eur J Cancer. 2016 Apr; 57:23-30.
Score: 0.033